Seattle Genetics to Present at Upcoming Investor Conferences

• Press Release
• Source: Seattle Genetics, Inc.
• On 4:05 pm EDT, Tuesday October 27, 2009

BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN - News) announced today that management will present at two upcoming investor conferences. The presentations will be webcast live and available for replay from Seattle Genetics’ website, www.seattlegenetics.com, under the "Investors and News" section.

Related Quotes

Symbol	Price	Change
SGEN	9.34	-0.06

{"s" : "sgen","k" : "c10,l10,p20,t10","o" : "","j" : ""}

Oppenheimer 20^th Annual Healthcare Conference

Todd E. Simpson, Chief Financial Officer, will present on Tuesday, November 3, 2009, at 2:10 p.m. Eastern Time. The conference is being held at the Waldorf-Astoria Hotel in New York City.

Lazard Capital Markets 6^th Annual Healthcare Conference

Clay B. Siegall, Ph.D., President & Chief Executive Officer, will present on Wednesday, November 18, 2009 at 1:15 p.m. Eastern Time. The conference is being held at The St. Regis Hotel in New York City.

About Seattle Genetics

Seattle Genetics is a clinical stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. The company’s lead product candidate, brentuximab vedotin (SGN-35), is in a pivotal trial under a special protocol assessment with the FDA. Brentuximab vedotin is empowered by Seattle Genetics’ proprietary antibody-drug conjugate (ADC) technology comprising highly potent synthetic drugs and stable linkers for attaching the drugs to monoclonal antibodies. In addition, Seattle Genetics has three other product candidates in ongoing clinical trials: lintuzumab (SGN-33), dacetuzumab (SGN-40) and SGN-70. Dacetuzumab is being developed under a worldwide collaboration with Genentech (a wholly-owned member of the Roche Group). Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Genentech, Bayer, CuraGen, a subsidiary of Celldex Therapeutics, Progenics, Daiichi Sankyo, MedImmune, a subsidiary of AstraZeneca, and Millennium: The Takeda Oncology Company, as well as an ADC co-development agreement with Agensys, a subsidiary of Astellas Pharma. More information can be found at www.seattlegenetics.com.

Seattle Genetics, Inc.
Peggy Pinkston, 425-527-4160
ppinkston@seagen.com